Dopamine agonists

P. Tuite, B. Ebbitt

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ropinirole) and apomorphine, another agonist presently under investigation, are discussed.

Original languageEnglish (US)
Pages (from-to)9-14
Number of pages6
JournalSeminars in Neurology
Issue number1
StatePublished - 2001


  • Dopamine agonists
  • Parkinson's disease
  • Parkinson's disease treatment


Dive into the research topics of 'Dopamine agonists'. Together they form a unique fingerprint.

Cite this